Kazia Therapeuticsの発行済株式数
Kazia Therapeuticsの発行済株式数は何ですか。
Kazia Therapeutics Limitedの発行済株式数は132.037Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
ASXのセクタHealth Careにおける発行済株式数の企業と比べるKazia Therapeutics
Kazia Therapeuticsは何をしますか。
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Kazia Therapeuticsと類似の発行済株式数
- Flir Systemsの発行済株式数は131.932Mです。
- Skyharbour Resourcesの発行済株式数は131.954Mです。
- Jubilant FoodWorksの発行済株式数は131.969Mです。
- Jubilant FoodWorksの発行済株式数は131.969Mです。
- Shanghai Jiaoda Withub Information Industrialの発行済株式数は132.000Mです。
- Upwork Incの発行済株式数は132.007Mです。
- Kazia Therapeuticsの発行済株式数は132.037Mです。
- Vulcan Materialsの発行済株式数は132.048Mです。
- Vulcan Materials Coの発行済株式数は132.060Mです。
- Coviaの発行済株式数は132.098Mです。
- REAの発行済株式数は132.117Mです。
- Albion Technology & General VCT Plcの発行済株式数は132.131Mです。
- Outcrop Goldの発行済株式数は132.149Mです。